First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors
Clinical trial NCT04528836 · TERMINATED
Trial details
- NCT number
- NCT04528836
- Sponsor
- Navire Pharma Inc., a BridgeBio company
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-12
- Primary completion
- 2024-03-22
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.